MANEWe were well into recruiting for our MANE Study.  This study requires healthy males and females aged 18 – 55 years with a Body Mass Index of less than 30 and weight of 50 to 100 kg.

Neulasta is an approved medication used to treat low white blood cells (infection fighting cells).  The MANE study is investigating a new drug which we will compare to Neulasta.

Every person in the study will receive two doses of either MSB11455 or Neulasta.  The two doses will be given 4-5 weeks apart.  each dose will be given as an injection under the skin.

Here is a link to the Full Study Information …